Human Longevity Offers 30x Whole-Genome Sequencing for USD 599

Human Longevity has made its Genomics for All whole-genome sequencing service available for $599, bringing technology previously used in the company’s higher-priced health programs into a standalone consumer offering.

The company says the service sequences all 6.4 billion base pairs of a person’s DNA at 30× coverage and delivers AI-interpreted results through the Human Longevity app. No clinic visit is required.

Reports can include inherited disease risks, pharmacogenomic markers affecting medication response, carrier status for hereditary conditions, and traits related to nutrition, metabolism, and exercise.

Background

Many consumer genetic tests use SNP chips to examine selected positions in the genome. Human Longevity says Genomics for All instead sequences the complete genome, creating a broader dataset that can be revisited as genetic research develops.

According to the company, its analysis examines more than 10,000 genetic variants. The pharmacogenomics component covers markers that may influence responses to commonly used medicines, including statins and GLP-1 receptor agonists.

The service also reports inherited disease predispositions and carrier status. These findings can identify potential risks, but they do not determine whether someone currently has—or will develop—a disease.

A Genome That Gets Re-Analysed

The central feature is ongoing reinterpretation. Human Longevity says it will re-analyse each customer’s genomic data as new research, disease-gene associations, and clinical guidelines become available.

When its system identifies a newly relevant finding, the company says it can alert affected customers, sometimes within 24 hours of publication. The release does not describe how findings are selected for notification or whether every alert receives individual clinical review.

Human Longevity chairman and CEO Wei-Wu He said the goal is to provide information that supports conversations with physicians and earlier awareness—not to replace doctors or make deterministic predictions.

What This Means

At $599, Genomics for All gives consumers a lower-priced entry point into Human Longevity’s precision-health platform. The company’s broader programs combine genomics with medical imaging, biomarker panels, and clinician-guided care.

The offering also reflects a shift in consumer genomics from collecting DNA once to repeatedly reinterpreting it. The sequence remains largely fixed, but its possible meaning can change as research and clinical guidance evolve.

That does not mean every reported association will be actionable. Genetic risk estimates vary in strength, and many common diseases are shaped by environment, behaviour, and other factors alongside DNA. Results should therefore be interpreted with a qualified healthcare professional.

What’s Next

Genomics for All is available now for $599 through Human Longevity.

The service sits alongside the company’s work on Human Life Foundation Models, an AI venture developed with Insilico Medicine. Human Longevity says that collaboration will use genomic and clinical data from more than 10,000 clients to study aging biology and predictive healthcare.

The Service at a Glance

• Product: Genomics for All
• Company: Human Longevity, Inc.
• Price: $599
• Availability: Available now
• Sequencing: Whole genome at 30× coverage
• Reported scope: More than 10,000 genetic variants
• Outputs: Disease-risk, pharmacogenomic, carrier-status, and health-trait reports
• Delivery: AI-interpreted results through the Human Longevity app
• Ongoing feature: Re-analysis as research and clinical guidance change
• Clinic visit: Not required